144P Toripalimab plus chemotherapy as neoadjuvant treatment for resectable stage IIB-IIIB NSCLC (RENAISSANCE study): A single-arm, phase II trial

S. Yan,J. Wang,C. Lyu,J. Bi,Y. Xin,B. Liu,S. Li, Y. Wang,J. Chen,X. Li,Y. Yang,N. Wu

Immuno-Oncology and Technology（2022）

引用 0|浏览2

暂无评分

摘要

Neoadjuvant chemoimmunotherapy have a promising efficacy in resectable non-small cell lung cancer (NSCLC). We aimed to investigate the efficacy and safety of neoadjuvant immunotherapy plus chemotherapy for stage IIB-IIIB NSCLC.

查看译文

关键词

neoadjuvant treatment,chemotherapy,toripalimab,iib-iiib,single-arm

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要